Opioid-free anesthesia with interfascial dexmedetomidine in a high-risk infant

ABSTRACT
Despite the advances in pediatric anesthesia, infants have higher mortality and critical incidents rates than children, especially ex-prematures and those with comorbidity. We present the case of a high-risk infant who underwent elective laparoscopic gastrostomy under opioid-free anesthesia (OFA) combined with transversus abdominis plane (TAP) block with Dexmedetomidine (DEX). Perioperative opioids were entirely avoided, and intraoperative anesthetics and postoperative analgesics were considerably reduced. The infant showed cardiorespiratory stability and optimal analgesia during the uneventful procedure and the postoperative period. We consider OFA and TAP block with DEX a safe and effective anesthetic combination for high-risk infants.

Key words: Anesthesia adjuvants; child; dexmedetomidine hydrochloride; high-risk infant; opioid-free anesthesia; TAP block

Introduction
Despite the remarkable reduction in mortality (0.6-0.1/10000) and critical incidents (0.14%) rates in pediatric anesthesia, infants (<1 year) have rated four and three times higher than children (>1 year), respectively. The most common critical incidents are respiratory events, medication errors, and equipment failures.[1,2]

The main risk factors in infants (in addition to age) are ex-prematurity and comorbidity (American Society of Anesthesiologists [ASA] physical status ≥3). Within the latter, the following conditions stand out: congenital heart diseases, genetic or metabolic disorders, neurological diseases, obstructive sleep apnea (OSA), bronchial hyperreactivity and processes that present with/lead to fever or require treatment.[1,2]

Adequate anesthetic management is considered a protective factor for high-risk infants. It is estimated that each year of experience reduces the risk of critical incidents by 1-2%. Therefore, it is recommended the management of high-risk infants in tertiary-level hospitals and by anesthesiologists with specific training in pediatric anesthesia and sufficient experience.[1,2]

Written informed consent for the present publication was obtained from the parents.

Case Description
We present the case of a 3-month-old term infant, ASA-III and weighing 6500 g, who underwent elective laparoscopic...
gastrostomy. The patient had a history of fetal macrosomia; severe hypoxic-ischemic encephalopathy with upper limb paresis; patent foramen ovale; moderate-severe pulmonary hypertension; mild left ventricular dysfunction with septal hypokinesia, treated with enalapril; right hemidiaphragmatic paralysis; gastroesophageal reflux treated with omeprazole and associated with apneic episodes and an episode of aspiration pneumonia; and catherization for removal of peripheral access central catheter fragment in pulmonary artery.

On arrival to the anteroom, the withdrawal of enalapril 24 hours earlier and a formula milk fast for ≥6 hours were verified. Once in the operating room, an ultrasound was performed for qualitative assessment of the pyloric antrum (Perlas classification grade 0) and inferior vena cava (collapsibility index > 50%). Subsequently, an inhalational induction was carried out with Sevoflurane 5% (up to the peripheral venous access cannulation) and Rocuronium 8 mg. Following the endotracheal intubation (cuffed tracheal tube n° 3 with cuff pressure adjustment using manometry), the patient was connected to mechanical ventilation (pressure controlled ventilation-volume guaranteed [PCV-VG] mode and the following parameters: driving pressure 15 cmH₂O; positive end-expiratory pressure 5 cmH₂O; minute ventilation 1.4 L/min; fresh gas flow 1.5 L/min; fraction of inspired oxygen 0.35) and ultrasound-guided bilateral subcostal TAP block was performed (Levobupivacaine 0.2% + DEX 6 mg, total volume 4 ml). Prior to the start of the surgical procedure, a 50 ml bolus of normal saline and Cefazolin 170 mg was administered.

Laparoscopic-assisted gastrostomy tube placement was performed using a pneumoperitoneum pressure of 8 mmHg and a gas flow of 1.4 L/min, with good hemodynamic tolerance. Anesthesia was maintained with Sevoflurane 1.8-2.2% (minimum alveolar concentration [MAC] 0.6-0.8); fluid therapy with Isosfundin® 40 ml/h; and Metamizole 200 mg + dexamethasone 3 mg + Ranitidine 10 mg + magnesium sulfate 225 mg were administered as analgesic adjuvants.

The following parameters were monitored: oxygen saturation, 99%; end-tidal carbon dioxide, 40 mmHg; heart rate, 105-120 bpm; systolic blood pressure, >70 mmHg; mean arterial pressure, >50 mmHg; perfusion index, >2%; bispectral index, 40-50; temperature, >36.5°C. After the procedure was completed (operative duration of 60 minutes), Sugammadex 15 mg was administered, and emergence from anesthesia and tracheal extubation was performed prior to transfer to pediatric intensive care unit (PICU). During the uneventful 4-hour stay in the PICU, the patient was awake and calm, with cardiorespiratory stability and good scores on pain (Face, Leg, Activity, Cry, Consolability [FLACC] scale 2) and Agitation (Pediatric Anesthesia Emergence Delirium [PAED] scale 1) scales. Eight hours later on the ward, the patient was stable and maintained good analgesia (FLACC 2) with no need for painkillers, although some irritability was observed (PAED 2-3), probably related to the prescribed postoperative 24-hour fast.

**Discussion**

Hypoxic-ischemic encephalopathy is one of the leading causes of full-term neonates’ morbidity and mortality. In developed countries, its incidence can reach 4/1000 live births and neonatal mortality is 25%. In the short term, lethargy, hypotonia/hyporeflexia, seizures, and respiratory and cardiovascular alterations may occur; while in the long term they may develop cerebral palsy, epilepsy, and cognitive/behavioral delay. Optimal perioperative management of these patients during infancy plays a crucial role in the prevention of neurological damage potential progression, and poses a challenge given the potential respiratory (i.e., apnea and persistent pulmonary hypertension) and cardiac (i.e., bradycardia, ventricular dysfunction and myocardial damage) comorbidity.[3,4]

In addition to the foregoing, there is the potential risk posed by anesthesia in neonates and infants on neurocognitive development, mainly owing to the following circumstances: cardiac surgery and neurosurgery, multiple exposures to general anesthetics, and alterations of brain homeostasis. Proper anesthetic management to counteract the latter entails accurately defining the events that may compromise blood flow and cerebral metabolism (i.e., hypotension, hypocapnia, hyperoxia, hypoglycemia or hyponatremia) and evaluating the benefit-risk of the various therapeutic measures.[5,6]

Opioids are potent analgesics widely prescribed in perioperative pain management. In parallel to their proven effectiveness, they exhibit potential side effects, both in the short term (i.e., nausea/vomiting, sedation, respiratory depression and paralytic ileus) and in the medium to long term (i.e., central sensitization, chronic pain and dependence), which can increase the length of stay and hospital costs. OFA reduces perioperative pain and postoperative analgesic requirements and avoids or minimizes the side effects of opioids. It is particularly interesting in fragile patients (neonates and infants) and those at risk of...
postoperative apnea (OSA, acute or chronic respiratory failure), as it facilitates spontaneous breathing recovery and early extubation, as well as reducing the length of stay in PICU. OFA rests on two pillars: regional anesthesia (neuraxial and peripheral) and multimodal analgesia (Paracetamol, steroidal and nonsteroidal anti-inflammatory drugs, \( \alpha \)-2 agonists, N-methyl-D-aspartate receptor antagonists, local anesthetics, and gabapentinoids).\(^7\)\(^9\)

Regional anesthesia allows preventing or reducing the doses of general anesthetics and opioids, counteracting the potential neurotoxic effects of the former and the respiratory and hemodynamic effects of both, as well as controlling pain and the neuroendocrine response associated with perioperative stress. In addition to its effectiveness, it has an optimal safety profile with a very low incidence of adverse events. It therefore represents a cornerstone of “low-neurotoxicity anesthesia” and OFA, being a technique of choice in high-risk infants.\(^10\)\(^12\)

DEX is a potent \( \alpha \)-2 adrenergic agonist, more selective and with a shorter half-life than Clonidine. DEX has sedative, analgesic, sympatholytic and organo-protective properties, causes minimal cardiorespiratory depression and has multiple routes of administration. Despite the U.S. Food and Drug Administration not approving its use in children or in regional anesthesia yet, DEX allows reducing Sevoflurane and intraoperative opioid requirements, prolongs the duration of postoperative analgesia and reduces the need for rescue analgesia. On the basis of the above, DEX is a very useful drug in pediatric anesthesia, especially in infants at risk of apnea, airway obstruction or respiratory distress, being one of the mainstays of “low-neurotoxicity” anesthesia and OFA. Interfascial block with DEX as an adjuvant (1-2 \( \mu \)g/kg) reduces local anesthetics doses and the risk of systemic toxicity. It also reduces pain and postoperative analgesia needs by >50%, and extends the duration of analgesia by >50% in the first 24 hours.\(^12\)\(^15\)

With regard to our case, the specific reasons behind opting for an OFA combined with a regional block were as follows: To enable early extubation and prevent or minimize postoperative apnea and respiratory failure episodes, by avoiding opioids in a patient with hemidiaphragmatic paralysis and previous apnea episodes; and to prevent or minimize potential low cardiac output and hypoxemia episodes associated with right-to-left shunt, by reducing the dose of Sevoflurane in a patient with left ventricular dysfunction, pulmonary hypertension and patent foramen ovale. The use of DEX in TAP block was indicated to enhance and prolong the perioperative analgesic effect, and to reduce the need for systemic agents in a high-risk infant.

It was remarkable that Sevoflurane requirements decreased significantly during the procedure, reaching a minimum dose of 1.8% (MAC 0.6) for a BIS of 40-50. In infants, the usual doses to achieve these BIS values are 2.5-3% (MAC 1), which would result in a 30-40% reduction. Such a reduction is more marked than that observed in this same block without DEX and is probably due to some degree of systemic absorption of DEX through the internal oblique and transverse muscles.

Our hospital is highly experienced in both opioid-sparing anesthesia and regional anesthesia techniques in pediatrics. However, the use of non-opioid adjuvants in regional blocks has been limited to magnesium sulfate and DEX via the epidural route. Recent use of DEX in peripheral blocks has been very well received, given the positive outcomes in terms of pain reduction and the need for perioperative anesthetics and analgesics, with consequent benefits for patients, especially those at higher risk.

In conclusion, we consider OFA a safe and effective technique to promote in the perioperative management of high-risk infants. The use of DEX in peripheral regional blocks is a very useful tool that allows it to be performed with greater success.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient’s parents have given their consent for the images and other clinical information to be reported in the journal. The patient’s parents understand that names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Lorinc AN, Walters CB, Lovejoy HK, Crockett CJ, Reddy SK. Hot topics in safety for pediatric anesthesia. Children (Basel) 2020;7:242.
2. Habre W, Disma N, Virag K, Becke K, Hansen TG, Jöhr M, et al. Incidence of severe critical events in paediatric anaesthesia (APRICOT): A prospective multicentre observational study in 261 hospitals in Europe. Lancet Respir Med 2017;5:412-25.
3. Szakmar E, Jermendy A, El-Dib M. Respiratory management during therapeutic hypothermia for hypoxic-ischemic encephalopathy.
Eizaga Rebollar, et al.: Interfascial dexmedetomidine in an infant

4. Popescu MR, Panaiteescu AM, Pavel B, Zagrean L, Peltecu G, Zagrean AM. Getting an early start in understanding perinatal asphyxia impact on the cardiovascular system. Front Pediatr 2019;8:68.

5. Hu D, Flick RP, Zacariello MJ, Colligan RC, Katusic SK, Schroeder DR, et al. Association between exposure of young children to procedures requiring general anesthesia and learning and behavioral outcomes in a population-based birth cohort. Anesthesiology 2017;127:227-40.

6. McCann ME, Lee JK, Inder T. Beyond anesthesia toxicity: Anesthetic considerations to lessen the risk of neonatal neurological injury. Anesth Analg 2019;129:1354-64.

7. Chia PA, Cannesson M, Myo Bui CC. Opioid free anesthesia: Feasible? Curr Opin Anesthesiol 2020;33:512-7.

8. Zhu A, Benzon HA, Anderson TA. Evidence for the efficacy of systemic opioid-sparing analgesics in pediatric surgical populations: A systematic review. Anesth Analg 2017;125:1569-87.

9. Franz AM, Martin LD, Liston DE, Latham GJ, Richards MJ, Low DK. In pursuit of an opioid-free pediatric ambulatory surgery center: A quality improvement initiative. Anesth Analg 2020;132:788-97.

10. Heydinger G, Tobias J, Veneziano G. Fundamentals and innovations in regional anaesthesia for infants and children. Anaesthesia 2021;76(Suppl 1):74-88.

11. Walker BJ, Long JB, Sathyamoorthy M, Bristler J, Wolf C, Bosenberg AT, et al. Complications in pediatric regional anesthesia: An analysis of more than 100,000 blocks from the pediatric regional anesthesia network. Anesthesiology 2020;129:721-32.

12. Eizaga Rebollar R, Garcia Palacios MV, Morales Guerrero J, Torres Morera LM. Neurotoxicity versus neuroprotection of anesthetics: Young children on the ropes? Paediatr Drugs 2017;19:271-5.

13. Mahmoud M, Barbi E, Mason KP. Dexmedetomidine: What’s new for pediatrics? A narrative review. J Clin Med 2020;9:2724.

14. Raof RA, El Metainy SA, Alia DA, Wahab MA. Dexmedetomidine decreases the required amount of bupivacaine for ultrasound-guided transversus abdominis plane block in pediatric patients: A randomized study. J Clin Anesth 2017;37:55-60.

15. Hartzell CJ, Long JB, White WM, Machado D, Austin TM. Ultrasound-guided bilateral rectus sheath block with or without dexmedetomidine in pediatric umbilical hernia repairs: A retrospective interrupted time series analysis. Reg Anesth Pain Med 2020;45:1021-2.